This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Geoff Hale, PhD
CEO at mAbsolve

Profile

Geoff has researched monoclonal antibodies since 1980. He was part of the team that developed the first humanized antibody (Campath-1H) and worked for 25 years at the Universities of Cambridge and Oxford to develop and manufacture antibodies for clinical trials. In 2002 Geoff founded BioAnaLab, a service laboratory specialising in the analysis of biologics. In 2009 the company was acquired by Millipore and Geoff continued as Chief Scientist until 2011.

Since then he has founded several other life science businesses and worked as a freelance scientist, consultant and company director, with interests in the development of antibodies and antigens for research, diagnosis and therapy.

Agenda Sessions

  • Diversity of Fc Effector Function in Antibody-Based Therapeutics

    08:15